Literature DB >> 16765138

CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?

Tom Schalekamp1, Gerard J J Boink, Loes E Visser, Bruno H Ch Stricker, Anthonius de Boer, Olaf H Klungel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16765138     DOI： 10.1016/j.clpt.2006.03.008

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  11 in total

Review 1.  Cost effectiveness of pharmacogenomics: a critical and systematic review.

Authors:  William B Wong; Josh J Carlson; Rahber Thariani; David L Veenstra
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Warfarin pharmacogenetics: economic considerations.

Authors:  Dyfrig A Hughes; Munir Pirmohamed
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 3.  Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines.

Authors:  Stefan Vegter; Cornelis Boersma; Mark Rozenbaum; Bob Wilffert; Gerjan Navis; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients.

Authors:  M V Lima; G S Ribeiro; E T Mesquita; P R Victer; R Vianna-Jorge
Journal:  Eur J Clin Pharmacol       Date:  2007-10-23       Impact factor: 2.953

5.  Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.

Authors:  Talitha I Verhoef; William K Redekop; Fazila Hasrat; Anthonius de Boer; Anke Hilse Maitland-van der Zee
Journal:  Am J Cardiovasc Drugs       Date:  2014-12       Impact factor: 3.571

6.  Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.

Authors:  Elizabeth J J Berm; Margot de Looff; Bob Wilffert; Cornelis Boersma; Lieven Annemans; Stefan Vegter; Job F M van Boven; Maarten J Postma
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

Review 7.  Evidence to Support Inclusion of Pharmacogenetic Biomarkers in Randomised Controlled Trials.

Authors:  Danielle Johnson; Dyfrig Hughes; Munir Pirmohamed; Andrea Jorgensen
Journal:  J Pers Med       Date:  2019-09-01

8.  Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.

Authors:  Ye Zhu; Kristi M Swanson; Ricardo L Rojas; Zhen Wang; Jennifer L St Sauver; Sue L Visscher; Larry J Prokop; Suzette J Bielinski; Liewei Wang; Richard Weinshilboum; Bijan J Borah
Journal:  Genet Med       Date:  2019-10-08       Impact factor: 8.822

Review 9.  A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.

Authors:  Catrin O Plumpton; Daniel Roberts; Munir Pirmohamed; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

Review 10.  Translating pharmacogenomics: challenges on the road to the clinic.

Authors:  Jesse J Swen; Tom W Huizinga; Hans Gelderblom; Elisabeth G E de Vries; Willem J J Assendelft; Julia Kirchheiner; Henk-Jan Guchelaar
Journal:  PLoS Med       Date:  2007-08       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.